Claims for Patent: 10,117,892

Summary for Patent: 10,117,892

Title:	Devices and methods for reducing the appearance of cellulite
Abstract:	Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
Inventor(s):	Perry; Tracy Ann (Santa Barbara, CA), Avelar; Rui (Santa Barbara, CA), Schwab; Justin (Santa Barbara, CA), Dominguez; Zachary (Santa Barbara, CA), Kayda; Edwin (Santa Barbara, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/473,319
Patent Claims:	1. A composition useful for reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient, the composition comprising: an injectable gel comprising: a mixture of at least collagenase I and collagenase II in a mass ratio of 1:1, the mixture having a specific activity of at least about 500 SRC units/mg; and at least one hyaluronic acid combined with or mixed with the collagenase I and collagenase II, the at least one hyaluronic acid present in an amount effective to provide a physical barrier between tissue planes to discourage regrowth of septal bands disrupted by the collagenase mixture: and at least one lipolytic agent capable of causing a reduction in the fat stores of adipocytes, wherein the at least one lipolytic agent is selected from the group consisting of phosphatidylcholine, conjugated linoleic acid, deoxycholate, magnolol, and a lipolytic enzyme. 2. The composition of claim 1, the mixture having specific activity from about 500 SRC units/mg to about 15,000 SRC units/mg. 3. The composition of claim 1, the mixture having specific activity of at least about 700 SRC units/mg. 4. The composition of claim 1, the mixture having specific activity of at least about 1000 SRC units/mg. 5. The composition of claim 1, the mixture having specific activity of at least about 1500 SRC units/mg. 6. The composition of claim 1, comprising the at least one hyaluronic acid in a concentration of between about 10 mg/mL and 40 mg/mL. 7. The composition of claim 1, wherein the at least one hyaluronic acid comprises a first and a second hyaluronic acid where the first hyaluronic acid has a higher viscosity than the second hyaluronic acid. 8. The composition of claim 1, wherein the at least one hyaluronic acid is a crosslinked hyaluronic acid. 9. The composition of claim 8, wherein the at least one hyaluronic acid is crosslinked with a crosslinker selected from the group consisting of glutaraldehyde (GTA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 1,4-butanediol diglycidyl ether (BDDE), and divinyl sulfone (DVS).

Details for Patent 10,117,892

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2033-08-29